BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30561126)

  • 1. Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database.
    Okada N; Niimura T; Zamami Y; Hamano H; Ishida S; Goda M; Takechi K; Chuma M; Imanishi M; Ishizawa K
    Cancer Med; 2019 Jan; 8(1):174-181. PubMed ID: 30561126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
    Cortes J; Mauro M; Steegmann JL; Saglio G; Malhotra R; Ukropec JA; Wallis NT
    Am J Hematol; 2015 Apr; 90(4):E66-72. PubMed ID: 25580915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
    Huang J; Cai J; Ye Q; Jiang Q; Lin H; Wu L
    BMJ Open; 2023 Aug; 13(8):e071456. PubMed ID: 37536976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
    Deremer DL; Ustun C; Natarajan K
    Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
    O'Hare T; Eide CA; Deininger MW
    Expert Opin Investig Drugs; 2008 Jun; 17(6):865-78. PubMed ID: 18491988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
    Kantarjian HM; Giles F; Gattermann N; Bhalla K; Alimena G; Palandri F; Ossenkoppele GJ; Nicolini FE; O'Brien SG; Litzow M; Bhatia R; Cervantes F; Haque A; Shou Y; Resta DJ; Weitzman A; Hochhaus A; le Coutre P
    Blood; 2007 Nov; 110(10):3540-6. PubMed ID: 17715389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacophore modeling of nilotinib as an inhibitor of ATP-binding cassette drug transporters and BCR-ABL kinase using a three-dimensional quantitative structure-activity relationship approach.
    Shukla S; Kouanda A; Silverton L; Talele TT; Ambudkar SV
    Mol Pharm; 2014 Jul; 11(7):2313-22. PubMed ID: 24865254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Jabbour E; Lipton JH
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):646-56. PubMed ID: 24095296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population.
    Suprapti B; Andarsari MR; Hapsari PP; Khotib J; ; Bintoro SUY
    J Basic Clin Physiol Pharmacol; 2020 Aug; 31(5):. PubMed ID: 32764164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
    Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
    Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
    Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
    Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature.
    Durand MJ; Hader SN; Derayunan A; Zinkevich N; McIntosh JJ; Beyer AM
    Microcirculation; 2020 Oct; 27(7):e12625. PubMed ID: 32395853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
    Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
    Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
    Jabbour E; Cortes J; Giles F; O'Brien S; Kantarijan H
    IDrugs; 2007 Jul; 10(7):468-79. PubMed ID: 17642017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
    Aichberger KJ; Herndlhofer S; Schernthaner GH; Schillinger M; Mitterbauer-Hohendanner G; Sillaber C; Valent P
    Am J Hematol; 2011 Jul; 86(7):533-9. PubMed ID: 21538470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies.
    Wang Z; Jiang L; Yan H; Xu Z; Luo P
    Expert Rev Clin Pharmacol; 2021 Apr; 14(4):445-456. PubMed ID: 33618586
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
    Haguet H; Douxfils J; Mullier F; Chatelain C; Graux C; Dogné JM
    Expert Opin Drug Saf; 2017 Jan; 16(1):5-12. PubMed ID: 27852118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.